Putting orphans where they belong - on the market
15 December 2009
Ian Schofield
Please Login to read the full article.
15 December 2009
Ian Schofield
With more major pharmaceutical companies entering the orphan drug field, attention is turning to how companies can ensure these expensive new medicines get onto the reimbursement lists of cash-strapped national authorities.
Developing drugs for rare diseases was territory previously reserved...
Please Login to read the full article.
RELATED CONTENT
NEWS
- PhRMA reports record number of rare disease drug candidates under development
- Patient access scheme prompts NICE U-turn on Novartis' Tasigna, while BMS will appeal against no for Sprycel
- Prosensa advances DMD candidates for GSK
- NICE recommends reduced-impact Mepact from Takeda for bone cancer
COMMENT
Other Informa Comment
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
